Safety Profile and Suicidality Associated with the Use of Esketamine in the Treatment of Major Depressive Disorder in European Countries: An EudraVigilance Database Analysis

<b>Background/Objective:</b> Major depressive disorder (MDD) is a common mental disorder, with a significant portion of patients developing treatment-resistant depression (TRD). Esketamine is an antagonist of the N-methyl-D-aspartate receptor indicated as a nasal spray in combination wit...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ilaria Ammendolia, Carmen Mannucci, Emanuela Esposito, Gioacchino Calapai, Mariaconcetta Currò, Paola Midiri, Cristina Mondello, Luigi Cardia, Fabrizio Calapai
Format:	Article
Language:	English
Published:	MDPI AG 2025-05-01
Series:	Pharmaceuticals
Subjects:	esketamine pharmacovigilance adverse reactions major depressive disorder treatment-resistant depression suicide
Online Access:	https://www.mdpi.com/1424-8247/18/5/702
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Adverse Reactions to the Orphan Drug Cerliponase Alfa in the Treatment of Neurolipofuscinosis Type 2 (CLN2)
by: Ilaria Ammendolia, et al.
Published: (2024-11-01)

Exploring the Cardiovascular Safety Profile of Ibuprofen: Insights from EudraVigilance Database
by: Cristina Anamaria Buciuman, et al.
Published: (2025-07-01)

Real-Life Data on the Safety of Pasireotide in Acromegaly: Insights from EudraVigilance
by: Ioana Rada Popa Ilie, et al.
Published: (2024-12-01)

Safety profile of tirzepatide: A real-world pharmacovigilance analysis of EudraVigilance database
by: Atul Khurana, et al.
Published: (2024-11-01)

Comparison Study of the Safety Profile of Olaparib Versus Niraparib: Analysis of Real-World Data from EudraVigilance
by: Desirèe Speranza, et al.
Published: (2025-04-01)

Bevacizumab—Insights from EudraVigilance Database on the Assessments of the Safety Profile of Monoclonal Antibodies Used as Targeted Cancer Treatment
by: Razvan Constantin Vonica, et al.
Published: (2025-03-01)

Comparative Pharmacovigilance Analysis of Approved and Repurposed Antivirals for COVID-19: Insights from EudraVigilance Data
by: Paul Andrei Negru, et al.
Published: (2025-06-01)

Comparative Analyses of the Safety Profiles of Vitamin D Receptor Agonists: A Pharmacovigilance Study Based on the EudraVigilance Database
by: Zsolt Gáll, et al.
Published: (2024-12-01)

Disproportionality Analysis of the Five Most Widespread Neurological Effects of COVID-19 Vaccines from 2021 to 2023: Insights from EudraVigilance
by: Arturo Gómez López de las Huertas, et al.
Published: (2025-04-01)

Serious adverse drug reactions associated with anti-SARS-CoV-2 vaccines and their reporting trends in the EudraVigilance database
by: Wojciech Nazar, et al.
Published: (2025-05-01)

Esketamine Optimized the Efficacy of Dexmedetomidine in Treating Sleep Disorders with Comorbid Depression
by: Ding Y, et al.
Published: (2025-07-01)

Benefits and risks of esketamine nasal spray continuation in treatment-resistant depression
by: Maxwell Z. Price, et al.
Published: (2024-12-01)

Efficacy and safety of ketamine and esketamine in reducing the incidence of postpartum depression: an updated systematic review and meta-analysis
by: Moaz Yasser Darwish, et al.
Published: (2025-02-01)

Insomnia and Esketamine Add-On Therapy to Antidepressant Therapy in Patients with Treatment-Resistant Depression—A Pilot Study
by: Daniel Szawarnoga, et al.
Published: (2025-07-01)

Efficacy of perioperative esketamine on postoperative depression: a systematic review and meta-analysis
by: Hao-Yan Li, et al.
Published: (2025-04-01)

Ketamine, Esketamine, and Arketamine: Their Mechanisms of Action and Applications in the Treatment of Depression and Alleviation of Depressive Symptoms
by: Piotr Kawczak, et al.
Published: (2024-10-01)

Comparative Efficacy of Esketamine vs Sufentanil with Propofol for Sedation in EUS: A Randomized, Controlled Study
by: Liu C, et al.
Published: (2025-01-01)

Research trends in esketamine for depression over the past decade: a bibliometric analysis
by: Baozhou Zhang, et al.
Published: (2025-06-01)

Auto-Induction in Oral Esketamine Treatment for Treatment-Resistant Depression: An Exploratory Study
by: Jolien K. E. Veraart, et al.
Published: (2025-04-01)

Case Report: Intranasal esketamine combined with a form of generative artificial intelligence in the management of treatment-resistant depression
by: Alexandre Fraichot, et al.
Published: (2025-08-01)

Effects of esketamine combined with thoracic paravertebral block on postoperative early sleep in patients undergoing thoracoscopic lobectomy
by: LI Wenyan, et al.
Published: (2024-12-01)

Esketamine use in real-world clinical practice in patients with treatment-resistant depression
by: Ismael Conejero, et al.

Network analysis of adverse event patterns following immunization with mRNA COVID-19 vaccines: real-world data from the European pharmacovigilance database EudraVigilance
by: Renato Ferreira-da-Silva, et al.
Published: (2025-02-01)

Effect of ketamine and esketamine on RNA expression and its relevance for depression: A systematic review
by: Claudia Pisanu, et al.
Published: (2025-09-01)

Does the intensity of dissociation predict antidepressant effects 24 hours after infusion of racemic ketamine or esketamine in treatment-resistant depression? A secondary analysis from a randomized controlled trial
by: Mariana V. F. Echegaray, et al.
Published: (2025-05-01)

Perioperative use of esketamine for the prevention of postpartum depression after cesarean section: a meta-analysis
by: Yanhong Li, et al.
Published: (2025-07-01)

Impact of esketamine intravenous analgesic pump on pain and depression post-cesarean
by: Xiao-Qiang Zhang, et al.
Published: (2025-04-01)

Effect of different administration methods of esketamine on postoperative depression in patients undergoing heart valve replacement
by: LI Zongxiao, MA Xin, MA Wenru, NIU Zejun
Published: (2025-06-01)

The effect of low-dose esketamine on maternal depression after cesarean delivery
by: Yan Shang, et al.
Published: (2025-12-01)

Long-Term Cognitive Outcomes of Esketamine Nasal Spray in Treatment-Resistant Depression: A Preliminary Report
by: Matildes de Freitas Menezes Sobreiro, et al.
Published: (2025-01-01)

Respiratory depression in women receiving propofol/esketamine versus propofol/fentanyl for abortion surgery or curettage: a randomized clinical trial
by: Cuiwen Zhang, et al.
Published: (2025-12-01)

Esketamine nasal spray compassionate use program in the Netherlands: An open label, multi-center cohort study in severe treatment-resistant depression
by: Abel (K.A.J.) Busz, et al.
Published: (2025-04-01)

Effects of epidural esketamine versus sufentanil on labor analgesia and postpartum depression: a retrospective cohort study
by: Kunyue Li, et al.
Published: (2025-01-01)

A Comparative Study of Esketamine-Propofol and Sufentanil-Propofol for Analgesia and Sedation During Breast Minimally Invasive Rotary Resection with Local Anesthesia: A Randomized Double-Blind Clinical Trial
by: Li N, et al.
Published: (2024-11-01)

Major Depressive Disorder with Suicidal Ideation or Intent in Taiwan: A Discrete Choice Experiment of Psychiatrists’ Treatment Preferences
by: Simon Fifer, et al.
Published: (2025-04-01)

Case Report: Successful management of psychogenic non-epileptic seizures with intranasal esketamine
by: Muneeb Hashmi, et al.
Published: (2025-04-01)

Cost-per-remitter for esketamine nasal spray versus quetiapine for treatment-resistant depression
by: Kristin Clemens, et al.
Published: (2025-06-01)

Application of remimazolam besylate combined with esketamine in outpatient colonoscopy in patients with hypertension
by: GUO Xiaoyang, LI Wei, HAO Zaijun
Published: (2025-05-01)

Effect of Low-Dose Esketamine Combined with Propofol on Postoperative Fatigue in Colonoscopy: A Randomized Clinical Trial
by: Sun X, et al.
Published: (2025-05-01)

Effect of Pretreatment with a Small Dose of Esketamine on Myoclonus Induced by Etomidate: A Randomized Controlled Trial
by: Gao L, et al.
Published: (2024-12-01)